Theraclion announces the signature of a commercial partnership with the University of Virginia (UVA), in the United States, for the use of Theraclion's latest technology in a new experimental breast cancer treatment.

This pilot study, which has received the green light from the FDA, will evaluate the combined effect of high-intensity focused ultrasound (HIFU) and low-dose chemotherapy on the immune response in patients with early-stage breast cancer.

If the combination of HIFU and chemotherapy thus enhances the immune response of patients, this combined treatment could offer early-stage breast cancer patients a better chance of survival", says the company.

Copyright (c) 2022 CercleFinance.com. All rights reserved.